Dynabeads CD3 Depletion Prototype Supporting Solutions From Development To Delivery

Allogeneic cell therapy manufacturing hinges on one critical challenge: removing CD3+ T cells with enough consistency and efficiency to build a scalable, reproducible process. Incomplete depletion compromises downstream purity, while rigid workflows slow development timelines. The Dynabeads CD3 Depletion prototype addresses both pressures, delivering residual CD3+ populations below 0.5% in knockout-modified cells and below 1% in PBMC populations, across multiple donors.

Built on the established Dynabeads magnetic separation platform and designed for compatibility with the automated CTS DynaCellect system, it bridges the gap between process development and GMP-ready manufacturing. With a single vial capacity of 4 billion labeled cells, teams can optimize at commercially relevant scale before committing to full production. Download the brochure to learn more.